As the clinical application of RET-selective TKIs expands, understanding their safety profile and potential side effects becomes increasingly important.20,21 As in our case, management of RET-selective TKI-induced LC requires a multidisciplinary approach, but appropriate diagnosis and treatment can allow for continuation of an otherwise effective oncological option. This evidence concerns the gene RET and laryngotracheoesophageal cleft.